Guideline Summary: Evidence‑Based Recommendations for Oxygen Delivery Devices

1. Nasal Cannula

• Nasal cannula is the first‑line device for most patients who need supplemental oxygen, according to the Thoracic Society. 1
• Flow rates of 1–6 L/min provide an approximate FiO₂ of 24–50 % (each additional L/min raises FiO₂ by ≈ 3–4 %). Moderate‑certainty evidence. 3
• At 2 L/min the delivered FiO₂ varies widely (≈ 24–35 %); at 5 L/min it is ≈ 40 %. Moderate‑certainty evidence. [3][5]
• The exact FiO₂ cannot be predicted precisely because it is affected by respiratory rate, tidal volume and breathing pattern. Moderate‑certainty evidence. 3
• Nasal cannula offers superior patient comfort compared with mask devices (Thoracic Society). 1
• It can be worn while eating, speaking and is less likely to be removed by patients (American Thoracic Society). 6
• No risk of CO₂ rebreathing and lower inspiratory resistance than face masks (American Thoracic Society). 6
• It is more cost‑effective and does not produce a claustrophobic sensation (Thoracic Society). 5
• Because FiO₂ delivery is unpredictable, nasal cannula is unsuitable when an exact oxygen concentration is required (e.g., calculating A‑a gradient). Moderate‑certainty evidence. 3
• Nasal irritation or soreness may occur at flows > 4 L/min; severe nasal congestion reduces effectiveness (Thoracic Society). 5
• Flow should be titrated according to pulse‑oximetry and arterial blood gas results (Thoracic Society). 3
• Mouth breathing does not diminish oxygen delivery and may increase FiO₂ (Thoracic Society). 5
• Most centers recommend humidification, although evidence for non‑heated humidification is lacking (American Thoracic Society). 6

2. Simple Face Mask

• Provides 40–60 % FiO₂ when flow is 5–10 L/min (Thoracic Society). 3
• Critical safety rule: flow must never be set below 5 L/min to avoid dangerous CO₂ rebreathing and increased inspiratory resistance (Thoracic Society). 3
• Less comfortable than nasal cannula and must be removed for meals (Thoracic Society).

3. Venturi (Fixed‑Performance) Mask

• Mandatory for patients who need precise FiO₂ control, especially those at risk of hypercapnic respiratory failure (Thoracic Society). 1
• Fixed FiO₂ options are 24 %, 28 %, 31 %, 35 %, 40 % and 60 % (Thoracic Society). 1
• Each FiO₂ setting requires a manufacturer‑specified flow rate (Thoracic Society). 3
• Indicated for:
  
  • Patients with COPD, obesity‑hypoventilation syndrome, or any condition predisposing to hypercapnic failure (Thoracic Society). 1
  • Patients with a resting respiratory rate > 30 breaths/min (Thoracic Society). 2
  • Cognitively impaired or confused patients to prevent inadvertent flow‑rate errors (Thoracic Society). 2
• For respiratory rates > 30 breaths/min, increase the flow above the minimum specified to maintain the intended FiO₂ (Thoracic Society). 2
• Target SpO₂ for hypercapnic‑risk patients is 88–92 % (not 94–98 %) (Thoracic Society). Moderate‑certainty evidence. 3
• Use a 24 % or 28 % Venturi mask, or nasal cannula at 1–2 L/min, to achieve the 88–92 % SpO₂ goal (Thoracic Society). 3

4. High‑Flow Nasal Cannula (HFNC)

• Indicated for acute hypoxemic respiratory failure and post‑extubation support; not for routine home oxygen (Thoracic Society). Moderate‑certainty evidence. 3
• Flow range 30–70 L/min; typical initial adult settings 40–50 L/min (35–60 L/min) with gas temperature 34–37 °C (Thoracic Society). Moderate‑certainty evidence. 3
• FiO₂ is titrated to target SpO₂ 94–98 % (or 88–92 % for hypercapnic‑risk patients) (Thoracic Society).
• Physiologic benefits (moderate certainty):
  
  • Delivers up to 60 L/min airflow matching inspiratory demand.
  • Provides reliable FiO₂ up to 100 %.
  • Generates low‑level PEEP (~7 cmH₂O at 50 L/min).
  • Supplies heated humidification that improves comfort and secretion clearance.
  • Reduces CO₂ washout of the upper airways.
• Clinical outcomes (moderate certainty):
  
  • May reduce intubation rates (RR 0.89; 95 % CI 0.77–1.02).
  • Short‑term mortality similar to conventional oxygen (RR 0.99; 95 % CI 0.84–1.17).
  • Significantly improves patient comfort versus reservoir masks.
  • Lowers respiratory rate by ≈ 2.3 breaths/min and raises PaO₂ by ≈ 17 mmHg.
  • Reduces re‑intubation risk (4.9 % vs 12.2 %; p = 0.04).
• Particularly beneficial for immunocompromised patients because of a lower risk of ventilator‑associated pneumonia (Thoracic Society).

5. High‑Concentration Reservoir (Non‑Rebreather) Mask

• Flow 15 L/min delivers 60–90 % FiO₂ (Thoracic Society). Moderate‑certainty evidence. 3
• Recommended as the initial method for severe hypoxemia in critically ill patients (Thoracic Society).

6. Oxygen‑Conserving Devices

• Deliver oxygen only during inspiration, reducing overall oxygen consumption by up to 50 % (Thoracic Society). Moderate‑certainty evidence. 1
• Indicated for ambulatory patients who need high flow rates and for patients who are active outside the home (Thoracic Society).
• Must be prescribed only after a formal ambulatory oxygen assessment (Thoracic Society).
• Limitations: variable ability to maintain target SaO₂ during exercise and possible failure to trigger in mouth‑breathing patients (Thoracic Society).

7. Trans‑Tracheal Oxygen

• Rarely used in home settings; requires a dedicated trained team (Thoracic Society).
• Reduces anatomical dead space, allowing lower flow rates than nasal cannula (Thoracic Society).
• Decreases work of breathing (Thoracic Society).
• Serious complications include catheter displacement, mucus obstruction and infection (Thoracic Society).

8. Tracheostomy Oxygen Delivery

• The tracheostomy collar is the most widely used delivery method (American Thoracic Society). Moderate‑certainty evidence. 6
• Enhanced humidification is advocated by most centers (American Thoracic Society).
• All patients receiving oxygen via tracheostomy must have humidified oxygen to maintain airway patency and reduce secretion buildup (Thoracic Society).

9. Face Tents and Head Hoods

• Limit patient mobility and visibility; CO₂ can accumulate if flow is insufficient; temperature and moisture buildup may occur (American Thoracic Society).

10. Humidification Guidelines

• Low‑flow oxygen (nasal cannula or masks) does not require humidification (Thoracic Society). Moderate‑certainty evidence. 3
• Short‑term high‑flow use (e.g., pre‑hospital) also does not require humidification (Thoracic Society).
• High‑flow systems used > 24 h, patients with upper‑airway dryness, and all patients with tracheostomy or artificial airways require humidification (Thoracic Society).
• Viscous secretions may be managed with nebulized saline (Thoracic Society).
• HFNC always incorporates heated humidification as part of the system (Thoracic Society).
• Bubble‑bottle humidifiers should be avoided because they provide no clinical benefit and pose infection risk (Thoracic Society).

11. Clinical Decision Algorithm for Hypoxemia

• Mild‑to‑moderate hypoxemia: start nasal cannula at 1–4 L/min (≈ 24–40 % FiO₂); target SpO₂ 94–98 % (Thoracic Society).
• Severe hypoxemia: begin with a high‑concentration reservoir mask at 15 L/min; consider HFNC if hypoxemia persists without hypercapnia (Thoracic Society).
• Hypercapnic‑risk patients (e.g., COPD, obesity‑hypoventilation): use a Venturi mask at 24 % or 28 % FiO₂, or nasal cannula at 1–2 L/min; target SpO₂ 88–92 % (Thoracic Society).
• At a nasal cannula flow of 6 L/min, hypercapnia may develop within 15 minutes (Thoracic Society).
• When precise FiO₂ control is unavailable, limit high‑flow oxygen to a maximum of 6 minutes (Thoracic Society).

12. Monitoring and Escalation

• Continuous pulse‑oximetry, arterial blood gases when indicated, respiratory rate and work of breathing should be monitored (Thoracic Society).

• Escalation pathway:

• Safety points: never operate a simple face mask below 5 L/min (CO₂ rebreathing risk); verify correct wall‑outlet connections; maintain prescribed oxygen delivery during nebulizer treatments.

13. Travel‑Related Oxygen Considerations

• Commercial aircraft cabins are maintained at 6,000–8,000 ft altitude; at 8,000 ft the inspired PO₂ is 118 mmHg versus 159 mmHg at sea level (American Thoracic Society).
• Patients on supplemental oxygen will need an increased FiO₂ at altitude (American Thoracic Society).
• Estimated FiO₂ adjustment formula: FiO₂ × (BP – 47) at ground level equals FiO₂ × (BP – 47) at altitude (American Thoracic Society).
• Recommendations: contact the airline well in advance, prefer direct flights, and arrange oxygen availability between connections (American Thoracic Society).
• Hypoxic challenge testing (inhaling 15–16 % O₂) can predict the effect of air travel on oxygenation (American Thoracic Society).

Ground Transportation

• Oxygen cylinders must be secured with a seat belt, foot‑well or car boot; liquid oxygen must be kept upright; a warning triangle may be displayed; insurers should be notified (Thoracic Society).

Portable Equipment

• Wheeled trolleys improve quality of life, walking distance and symptoms in patients able to walk > 300 m (Thoracic Society).
• Less‑able patients find trolleys easier to use than backpacks (Thoracic Society).